Hvilken er prisen på Scilex Holding Company (SCLX)

Prisen på Scilex Holding Company (SCLX) er $5.61

Hva er markedsverdien på Scilex Holding Company (SCLX)

Markedsverdien på Scilex Holding Company (SCLX) er $47.65M

Scilex Holding Company (SCLX) Fortjeneste per Aksje

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

År	EPS	Endre
Ikke nok data for de angitte datoene.

År

EPS

Endre

Ikke nok data for de angitte datoene.

Selskap	EPS	EPS-forskjell	Land
Eli Lilly and Company LLY.US	$29.85	-	US
Johnson & Johnson JNJ.US	$8.65	-	US
AbbVie Inc. ABBV.US	$3.55	-	US
Roche Holding AG RO.SW	$20.39	-	CH
Merck & Co., Inc. MRK.US	$1.26	-	US

Selskap

EPS

EPS-forskjell

Land